InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-0
Post# of 228
(Total Views: 107)
Posted On: 07/24/2024 4:11:37 PM
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
- Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces
- InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need
- Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model
Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces. InMed Pharmaceuticals (NASDAQ: INM), a clinical stage company developing a pipeline of pharmaceutical drug candidates to treat several diseases with a high unmet medical need, is at the forefront of developing innovative treatments for this debilitating condition, with their flagship product INM-089 showing great promise.
AMD is the leading cause of vision loss among people aged 50 and older. It comes in two forms: dry AMD, which is more common and less severe, and wet AMD, which is rarer but more severe. The exact cause of AMD is not fully understood, but it is believed to involve a combination of genetic and environmental factors.
Results from several in vitro and in vivo studies demonstrated several pharmacological effects in the potential treatment of dry AMD. These include:
- providing neuroprotection of photoreceptors and improving photoreceptor function
- preserving retinal function in the back of the eye
- improving integrity of the retinal pigment epithelium (“RPE”)
- improve the thickness of “outer nuclear layer” (“ONL”) of the retina where photoreceptors are located (Based on widely accepted ocular research, the thickness of the outer nuclear layer is strongly correlated with photoreceptor preservation and visual acuity.)
INM-089 is also a proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). CB1 and CB2 receptors are both part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses.
InMed’s commitment to scientific excellence is reflected in its robust pipeline of cannabinoid-based treatments. In addition to INM-089 for AMD, the company is developing therapies for other serious conditions, including dermatological and Alzheimer’s diseases. Their research and development efforts are supported by a team of experienced scientists and industry professionals dedicated to bringing new treatments to market.
As InMed continues to advance INM-089 through pre-clinical studies, the company’s commitment to innovation and patient care remains steadfast. The future looks promising for those affected by AMD, thanks to the pioneering efforts of InMed Pharmaceuticals and their dedication to developing life-changing therapies.
For more information, visit the company’s website at www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://nnw.fm/INM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces
- InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need
- Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model
Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces. InMed Pharmaceuticals (NASDAQ: INM), a clinical stage company developing a pipeline of pharmaceutical drug candidates to treat several diseases with a high unmet medical need, is at the forefront of developing innovative treatments for this debilitating condition, with their flagship product INM-089 showing great promise.
AMD is the leading cause of vision loss among people aged 50 and older. It comes in two forms: dry AMD, which is more common and less severe, and wet AMD, which is rarer but more severe. The exact cause of AMD is not fully understood, but it is believed to involve a combination of genetic and environmental factors.
Results from several in vitro and in vivo studies demonstrated several pharmacological effects in the potential treatment of dry AMD. These include:
- providing neuroprotection of photoreceptors and improving photoreceptor function
- preserving retinal function in the back of the eye
- improving integrity of the retinal pigment epithelium (“RPE”)
- improve the thickness of “outer nuclear layer” (“ONL”) of the retina where photoreceptors are located (Based on widely accepted ocular research, the thickness of the outer nuclear layer is strongly correlated with photoreceptor preservation and visual acuity.)
INM-089 is also a proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). CB1 and CB2 receptors are both part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses.
InMed’s commitment to scientific excellence is reflected in its robust pipeline of cannabinoid-based treatments. In addition to INM-089 for AMD, the company is developing therapies for other serious conditions, including dermatological and Alzheimer’s diseases. Their research and development efforts are supported by a team of experienced scientists and industry professionals dedicated to bringing new treatments to market.
As InMed continues to advance INM-089 through pre-clinical studies, the company’s commitment to innovation and patient care remains steadfast. The future looks promising for those affected by AMD, thanks to the pioneering efforts of InMed Pharmaceuticals and their dedication to developing life-changing therapies.
For more information, visit the company’s website at www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://nnw.fm/INM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)